Clinuvel Pharmaceuticals Limited (CUV.AX)
AUD 11.42
(-1.47%)
AUD 11.42
(-1.47%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 | 49.14 Million AUD | 20.14% |
| 2023 | 40.9 Million AUD | 23.66% |
| 2022 | 33.08 Million AUD | 23.92% |
| 2021 | 26.69 Million AUD | 161.82% |
| 2020 | 10.19 Million AUD | -38.91% |
| 2019 | 16.69 Million AUD | 36.65% |
| 2018 | 12.21 Million AUD | 79.65% |
| 2017 | 6.79 Million AUD | 291.55% |
| 2016 | -3.54 Million AUD | 67.22% |
| 2015 | -10.82 Million AUD | -85.72% |
| 2014 | -5.82 Million AUD | 29.6% |
| 2013 | -8.28 Million AUD | 19.65% |
| 2012 | -10.3 Million AUD | 19.05% |
| 2011 | -12.73 Million AUD | 22.27% |
| 2010 | -16.37 Million AUD | 9.97% |
| 2009 | -18.19 Million AUD | 3.49% |
| 2008 | -18.84 Million AUD | -67.19% |
| 2007 | -11.27 Million AUD | -3.41% |
| 2006 | -10.9 Million AUD | 11.58% |
| 2005 | -12.32 Million AUD | -41.15% |
| 2004 | -8.73 Million AUD | -78.0% |
| 2003 | -4.9 Million AUD | -17.27% |
| 2002 | -4.18 Million AUD | -112.83% |
| 2001 | -1.96 Million AUD | 0.0% |
| 2000 | - AUD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 FY | 55.13 Million AUD | 34.77% |
| 2024 Q2 | 11.33 Million AUD | 0.0% |
| 2024 Q4 | 34.67 Million AUD | 0.0% |
| 2023 Q4 | 27.93 Million AUD | 0.0% |
| 2023 FY | 40.9 Million AUD | 23.66% |
| 2023 Q2 | 12.97 Million AUD | 0.0% |
| 2022 FY | 33.08 Million AUD | 23.92% |
| 2022 Q2 | 8.42 Million AUD | 0.0% |
| 2022 Q4 | 24.62 Million AUD | 0.0% |
| 2021 FY | 26.69 Million AUD | 161.82% |
| 2021 Q2 | 6.2 Million AUD | 0.0% |
| 2021 Q4 | 20.51 Million AUD | 0.0% |
| 2020 Q4 | 10.65 Million AUD | 0.0% |
| 2020 Q2 | 1.9 Million AUD | 0.0% |
| 2020 FY | 10.19 Million AUD | -38.91% |
| 2019 Q2 | 3.29 Million AUD | 0.0% |
| 2019 Q4 | 13.39 Million AUD | 0.0% |
| 2019 FY | 16.69 Million AUD | 36.65% |
| 2018 FY | 12.21 Million AUD | 79.65% |
| 2018 Q4 | 11.03 Million AUD | 0.0% |
| 2018 Q2 | 1.17 Million AUD | 0.0% |
| 2017 Q2 | 2.49 Million AUD | 0.0% |
| 2017 FY | 6.79 Million AUD | 291.55% |
| 2017 Q4 | 4.3 Million AUD | 0.0% |
| 2016 Q4 | -97.66 Thousand AUD | 0.0% |
| 2016 FY | -3.54 Million AUD | 67.22% |
| 2016 Q2 | -3.45 Million AUD | 0.0% |
| 2015 FY | -10.82 Million AUD | -85.72% |
| 2015 Q4 | -3.17 Million AUD | 0.0% |
| 2015 Q2 | -7.65 Million AUD | 0.0% |
| 2014 Q2 | -3.42 Million AUD | 0.0% |
| 2014 Q4 | -2.4 Million AUD | 0.0% |
| 2014 FY | -5.82 Million AUD | 29.6% |
| 2013 Q3 | -2.05 Million AUD | 54.82% |
| 2013 Q4 | -2.73 Million AUD | -33.06% |
| 2013 FY | -8.28 Million AUD | 19.65% |
| 2013 Q1 | -2.56 Million AUD | 0.0% |
| 2013 Q2 | -4.55 Million AUD | -77.68% |
| 2012 Q2 | -2.56 Million AUD | 18.95% |
| 2012 FY | -10.3 Million AUD | 19.05% |
| 2012 Q4 | -2.56 Million AUD | 0.0% |
| 2012 Q3 | -2.56 Million AUD | 0.0% |
| 2012 Q1 | -3.15 Million AUD | 0.0% |
| 2011 Q1 | -3.91 Million AUD | 0.0% |
| 2011 Q2 | -3.15 Million AUD | 19.3% |
| 2011 FY | -12.73 Million AUD | 22.27% |
| 2011 Q3 | -3.15 Million AUD | 0.0% |
| 2011 Q4 | -3.15 Million AUD | 0.0% |
| 2010 Q2 | -3.91 Million AUD | 9.79% |
| 2010 Q4 | -3.91 Million AUD | 0.0% |
| 2010 FY | -16.37 Million AUD | 9.97% |
| 2010 Q1 | -4.34 Million AUD | 0.0% |
| 2010 Q3 | -3.91 Million AUD | 0.0% |
| 2009 Q1 | -4.5 Million AUD | 0.0% |
| 2009 Q3 | -4.34 Million AUD | 0.0% |
| 2009 Q2 | -4.34 Million AUD | 3.59% |
| 2009 Q4 | -4.34 Million AUD | 0.0% |
| 2009 FY | -18.19 Million AUD | 3.49% |
| 2008 Q2 | -4.5 Million AUD | -73.67% |
| 2008 Q1 | -2.59 Million AUD | 0.0% |
| 2008 FY | -18.84 Million AUD | -67.19% |
| 2008 Q4 | -4.5 Million AUD | 0.0% |
| 2008 Q3 | -4.5 Million AUD | 0.0% |
| 2007 Q3 | -2.59 Million AUD | 0.0% |
| 2007 Q2 | -2.59 Million AUD | -3.82% |
| 2007 FY | -11.27 Million AUD | -3.41% |
| 2007 Q1 | -2.49 Million AUD | 0.0% |
| 2007 Q4 | -2.59 Million AUD | 0.0% |
| 2006 FY | -10.9 Million AUD | 11.58% |
| 2006 Q3 | -2.49 Million AUD | 0.0% |
| 2006 Q1 | -2.87 Million AUD | 0.0% |
| 2006 Q4 | -2.49 Million AUD | 0.0% |
| 2006 Q2 | -2.49 Million AUD | 13.2% |
| 2005 Q2 | -2.87 Million AUD | -44.82% |
| 2005 Q4 | -2.87 Million AUD | 0.0% |
| 2005 Q3 | -2.87 Million AUD | 0.0% |
| 2005 Q1 | -1.98 Million AUD | 0.0% |
| 2005 FY | -12.32 Million AUD | -41.15% |
| 2004 Q3 | -1.98 Million AUD | 0.0% |
| 2004 Q4 | -1.98 Million AUD | 0.0% |
| 2004 FY | -8.73 Million AUD | -78.0% |
| 2004 Q1 | -1.02 Million AUD | 0.0% |
| 2004 Q2 | -1.98 Million AUD | -93.16% |
| 2003 Q1 | -849.68 Thousand AUD | 0.0% |
| 2003 FY | -4.9 Million AUD | -17.27% |
| 2003 Q3 | -1.02 Million AUD | 0.0% |
| 2003 Q4 | -1.02 Million AUD | 0.0% |
| 2003 Q2 | -1.02 Million AUD | -21.02% |
| 2002 Q3 | -849.68 Thousand AUD | 0.0% |
| 2002 Q2 | -849.68 Thousand AUD | -72.85% |
| 2002 Q4 | -849.68 Thousand AUD | 0.0% |
| 2002 Q1 | -491.56 Thousand AUD | 0.0% |
| 2002 FY | -4.18 Million AUD | -112.83% |
| 2001 Q3 | -491.56 Thousand AUD | 0.0% |
| 2001 Q2 | -491.56 Thousand AUD | 0.0% |
| 2001 Q1 | - AUD | 0.0% |
| 2001 FY | -1.96 Million AUD | 0.0% |
| 2001 Q4 | -491.56 Thousand AUD | 0.0% |
| 2000 Q4 | - AUD | 0.0% |
| 2000 Q3 | - AUD | 0.0% |
| 2000 FY | - AUD | 0.0% |
| 2000 Q2 | - AUD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AdAlta Limited | -5.26 Million AUD | 1034.093% |
| Acrux Limited | -9.83 Million AUD | 599.778% |
| Actinogen Medical Limited | -12.83 Million AUD | 482.804% |
| AnteoTech Limited | -11.72 Million AUD | 519.117% |
| Argenica Therapeutics Limited | -5.67 Million AUD | 966.627% |
| Arovella Therapeutics Limited | -7.19 Million AUD | 783.273% |
| Anatara Lifesciences Ltd | -1.45 Million AUD | 3468.327% |
| Alterity Therapeutics Limited | -19.6 Million AUD | 350.734% |
| Amplia Therapeutics Limited | -4.42 Million AUD | 1210.7% |
| Avecho Biotechnology Limited | -4.58 Million AUD | 1170.955% |
| Bio-Gene Technology Limited | -3.06 Million AUD | 1704.857% |
| Biome Australia Limited | -1.91 Million AUD | 2668.845% |
| Biotron Limited | -5.15 Million AUD | 1054.117% |
| Botanix Pharmaceuticals Limited | -14.69 Million AUD | 434.345% |
| BTC Health Limited | 1.05 Million AUD | -4557.327% |
| Chimeric Therapeutics Limited | -12.3 Million AUD | 499.265% |
| CSL Limited | 5.64 Billion AUD | 99.13% |
| Clarity Pharmaceuticals Ltd | -44.8 Million AUD | 209.704% |
| Cynata Therapeutics Limited | -8.8 Million AUD | 658.0% |
| Dimerix Limited | -25.05 Million AUD | 296.124% |
| EZZ Life Science Holdings Limited | 9.71 Million AUD | -405.818% |
| Hexima Limited | -1 Million AUD | 4972.185% |
| Island Pharmaceuticals Limited | -2.87 Million AUD | 1810.227% |
| Immuron Limited | -5.8 Million AUD | 947.219% |
| Immutep Limited | -44.93 Million AUD | 209.371% |
| Imugene Limited | -140.93 Million AUD | 134.874% |
| Invex Therapeutics Ltd | -2.13 Million AUD | 2403.503% |
| Memphasys Limited | -2.7 Million AUD | 1917.61% |
| Nanollose Limited | -1.24 Million AUD | 4032.404% |
| Neuren Pharmaceuticals Limited | 225.96 Million AUD | 78.249% |
| Noxopharm Limited | -7.53 Million AUD | 752.265% |
| NeuroScientific Biopharmaceuticals Limited | -2.05 Million AUD | 2489.824% |
| Nyrada Inc. | -4.56 Million AUD | 1177.733% |
| Orthocell Limited | -11.68 Million AUD | 520.749% |
| PharmAust Limited | -6.65 Million AUD | 838.112% |
| Patrys Limited | -3.53 Million AUD | 1488.7% |
| Paradigm Biopharmaceuticals Limited | -65.11 Million AUD | 175.482% |
| Proteomics International Laboratories Limited | -7.23 Million AUD | 779.635% |
| Prescient Therapeutics Limited | -7.18 Million AUD | 783.904% |
| PYC Therapeutics Limited | -38.85 Million AUD | 226.484% |
| Race Oncology Limited | -13.38 Million AUD | 467.31% |
| Radiopharm Theranostics Limited | -47.2 Million AUD | 204.106% |
| Recce Pharmaceuticals Ltd | -22.05 Million AUD | 322.882% |
| Starpharma Holdings Limited | -15.15 Million AUD | 424.218% |
| Telix Pharmaceuticals Limited | - AUD | -Infinity% |
| Tissue Repair Ltd | -4.87 Million AUD | 1107.971% |
| Zelira Therapeutics Limited | -5.93 Million AUD | 927.657% |